When.com Web Search

  1. Ads

    related to: current gene therapy

Search results

  1. Results From The WOW.Com Content Network
  2. Current Gene Therapy - Wikipedia

    en.wikipedia.org/wiki/Current_Gene_Therapy

    Current Gene Therapy is a peer-reviewed medical journal published by Bentham Science Publishers. The editor-in-chief is Liang Cheng ( Harbin Medical University Harbin, China). The focus of this journal is pre-clinical or clinical research on gene therapy.

  3. Gene therapy - Wikipedia

    en.wikipedia.org/wiki/Gene_therapy

    Gene therapy is a medical technology ... it was reported that it had been developed a new method to affect genetic expressions through direct current. [301] In ...

  4. List of gene therapies - Wikipedia

    en.wikipedia.org/wiki/List_of_gene_therapies

    Current events; Random article; About Wikipedia; ... This article contains a list of commercially available gene therapies. Gene therapies ... "Gene Therapy Arrives".

  5. Gene therapy for color blindness - Wikipedia

    en.wikipedia.org/wiki/Gene_therapy_for_color...

    Animal testing for gene therapy began in 2007 with a 2009 breakthrough in squirrel monkeys suggesting an imminent gene therapy in humans. While progress in gene therapy for red-green color blindness has slowed since then, successful human trials are currently underway for achromatopsia, a different form of color vision deficiency.

  6. Vectors in gene therapy - Wikipedia

    en.wikipedia.org/wiki/Vectors_in_gene_therapy

    How vectors work to transfer genetic material. Gene therapy utilizes the delivery of DNA into cells, which can be accomplished by several methods, summarized below. The two major classes of methods are those that use recombinant viruses (sometimes called biological nanoparticles or viral vectors) and those that use naked DNA or DNA complexes (non-viral methods).

  7. Virotherapy - Wikipedia

    en.wikipedia.org/wiki/Virotherapy

    In 2017, the FDA approved Spark Therapeutics' Luxturna, an AAV vector-based gene therapy product for the treatment of RPE65 mutation-associated retinal dystrophy in adults. [28] [29] Luxturna is the first gene therapy approved in the US for the treatment of a monogenetic disorder. [28] [30] It has been authorized for use in the EU since 2018. [31]

  1. Ad

    related to: current gene therapy